SPIKIMM receives 15 Million Euros in non-dilutive funding awarded by France 2030 to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-COV-2

SpikImm, a biotech company founded in 2021 by Truffle Capital in collaboration with the Pasteur Institute, has been awarded a €15 million non-dilutive financing from the French government France 2030 program for its "PROPHYMAB" project, which is supported as part of the "Emerging Infectious Diseases and CBRN Threats" Acceleration Strategy.

The health component of France 2030 "Innovation Santé 2030" provides a set of legislative and regulatory incentives and 7.5 billion euros funding to make France the most innovative and sovereign nation in Europe for healthcare. Within this Acceleration Strategy framework, SpikImm had previously obtained a grant of 2.2 million euros for its preclinical and CMC development.